Exagen Closes Public Offering, Raises $20.2 Million

Exagen ( (XGN) ) has provided an announcement.

On May 9, 2025, Exagen Inc. successfully closed its public offering of 3,350,000 shares of common stock at $5.25 per share, raising approximately $18.6 million in net proceeds. The offering, which included the full exercise of the underwriter’s option to purchase an additional 502,500 shares, resulted in gross proceeds of about $20.2 million, enhancing Exagen’s financial position and potentially strengthening its market presence in the autoimmune diagnostics industry.

Spark’s Take on XGN Stock

According to Spark, TipRanks’ AI Analyst, XGN is a Neutral.

Exagen’s overall score reflects strong revenue growth and positive technical indicators. However, high leverage, negative cash flows, and unattractive valuation weigh heavily on the stock’s outlook. Strategic initiatives and recent financial arrangements provide potential for improved stability and growth in the future.

To see Spark’s full report on XGN stock, click here.

More about Exagen

Exagen Inc. is a leading provider of autoimmune diagnostics based in San Diego County, California. The company focuses on transforming care for patients with chronic autoimmune conditions through its innovative testing portfolio. Its flagship product, AVISE® CTD, aids in diagnosing complex autoimmune diseases such as lupus, rheumatoid arthritis, and Sjögren’s syndrome with greater accuracy.

Average Trading Volume: 161,887

Technical Sentiment Signal: Buy

Current Market Cap: $123M

For a thorough assessment of XGN stock, go to TipRanks’ Stock Analysis page.